We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




CRP Testing Takes on New Importance

By HospiMedica staff writers
Posted on 11 Jan 2005
With two new studies showing that knowing C-reactive protein (CRP) levels are just as important as knowing cholesterol in lowering the risk of heart disease, CRP testing can be expected to grow in the future.

In one study involving 3,745 patients receiving statin therapy, researchers at Brigham and Women's Hospital (BWH, Boston, MA, USA) found that lowering low-density lipoprotein (LDL) was not enough, that CRP also needed to be lowered to less than 2 mg/l in order to achieve the greatest clinical benefit. More...
In fact, patients who had low CRP levels after statin treatment did significantly better than those with high CRP levels, regardless of the level of LDL cholesterol attained. The lowest level of risk was found in patients with LDL of less than 70 mg/dl and a CRP of less than 2 mg/l. The study was published in the January 6, 2005, issue of The New England Journal of Medicine.

"These new data confirm the crucial role inflammation plays in heart disease,” noted lead author Paul M. Ridker, M.D., of BWH. "The data also provide the first hard evidence that lowering CRP levels is associated with clinical benefits for our patients.”

In another study, published in the same issue of The New England Journal of Medicine, researchers at the Cleveland Clinic (OH, USA) demonstrated that the rate of progression of atherosclerosis is slowed among patients who received the greatest CRP reduction after initiating statin therapy.

"Physicians prescribing statin therapy need to monitor CRP levels as well as cholesterol levels if they want to get the best results for their patients,” remarked Eugene Braunwald, M.D., professor, Harvard Medical School.





Related Links:
Brigham and Women's
Cleveland Clinic

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Resorbable Bovine Collagen Membrane
GenDerm
Monitor/Defibrillator
Zenix
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.